Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study - PubMed
Randomized Controlled Trial
doi: 10.1111/j.1440-1819.2009.02032.x. Epub 2009 Nov 24.
Affiliations
- PMID: 19968833
- DOI: 10.1111/j.1440-1819.2009.02032.x
Free article
Randomized Controlled Trial
Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study
Moon-Soo Lee et al. Psychiatry Clin Neurosci. 2010 Feb.
Free article
Abstract
Aim: The objective of the present study was to assess the efficacy and safety of bromocriptine treatment for patients with antipsychotic-drug-induced hyperprolactinemia in clinical practice.
Methods: This was an 8-week randomized, single-blind, placebo-controlled, multicenter study. Sixty female schizophrenia patients were enrolled and were randomly assigned to one of four treatment groups: bromocriptine 2.5 mg/day, 5 mg/day, 10 mg/day, and placebo. Serum levels of prolactin, estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were evaluated on three occasions (baseline, and 4 and 8 weeks after commencement of the treatment paradigm). Extrapyramidal symptoms (EPS) and clinical symptoms were assessed using the Simpson-Angus scale and the Positive and Negative Syndrome Scale (PANSS), respectively.
Results: Of the 60 subjects who were enrolled, 48 completed the study (n = 14, 13, 11, and 10 in the bromocriptine 2.5 mg/day, 5 mg/day, and 10 mg/day, and placebo groups, respectively). Four patients in the 10-mg/day group, two in the 5-mg/day group, and one in the placebo group resumed menses during the study. The mean level of prolactin significantly decreased from baseline to week 4, and then plateaued, showing no significant change for the remaining 4 weeks of the study. No significant changes in LH, FSH, or E2 levels were observed throughout the 8-week study period, either within or between groups.
Conclusion: Administration of bromocriptine is a safe method for treating antipsychotic-drug-induced hyperprolactinemia without exacerbating either psychotic symptoms or EPS.
Similar articles
-
Yuan HN, Wang CY, Sze CW, Tong Y, Tan QR, Feng XJ, Liu RM, Zhang JZ, Zhang YB, Zhang ZJ. Yuan HN, et al. J Clin Psychopharmacol. 2008 Jun;28(3):264-370. doi: 10.1097/JCP.0b013e318172473c. J Clin Psychopharmacol. 2008. PMID: 18480682 Clinical Trial.
-
Nakajima M, Terao T, Iwata N, Nakamura J. Nakajima M, et al. Pharmacopsychiatry. 2005 Jan;38(1):17-9. doi: 10.1055/s-2005-837766. Pharmacopsychiatry. 2005. PMID: 15706461
-
Bliesener N, Yokusoglu H, Quednow BB, Klingmüller D, Kühn KU. Bliesener N, et al. Pharmacopsychiatry. 2004 Jul;37(4):189-91. doi: 10.1055/s-2004-827176. Pharmacopsychiatry. 2004. PMID: 15467977 Clinical Trial. No abstract available.
-
Antipsychotic-induced hyperprolactinaemia.
Inder WJ, Castle D. Inder WJ, et al. Aust N Z J Psychiatry. 2011 Oct;45(10):830-7. doi: 10.3109/00048674.2011.589044. Epub 2011 Jun 30. Aust N Z J Psychiatry. 2011. PMID: 21714721 Review.
-
New drugs for hyperprolactinaemia.
[No authors listed] [No authors listed] Drug Ther Bull. 1995 Sep;33(9):65-7. doi: 10.1136/dtb.1995.33965. Drug Ther Bull. 1995. PMID: 7588002 Review.
Cited by
-
Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, Casulari LA, Cunha Neto MBC, Czepielewski MA, Duarte FHG, Faria MDS, Gadelha MR, Garmes HM, Glezer A, Gurgel MH, Jallad RS, Martins M, Miranda PAC, Montenegro RM, Musolino NRC, Naves LA, Ribeiro-Oliveira Júnior A, Silva CMS, Viecceli C, Bronstein MD. Vilar L, et al. Arch Endocrinol Metab. 2018 Mar-Apr;62(2):236-263. doi: 10.20945/2359-3997000000032. Arch Endocrinol Metab. 2018. PMID: 29768629 Free PMC article. Review.
-
Kim HR, Kim SM, Kang WS, Jeon HJ, Jang SH, Jon DI, Hong J, Jeong JH. Kim HR, et al. Clin Psychopharmacol Neurosci. 2023 Aug 31;21(3):447-456. doi: 10.9758/cpn.22.979. Clin Psychopharmacol Neurosci. 2023. PMID: 37424413 Free PMC article.
-
Management of antipsychotic-induced hyperprolactinemia.
Tewksbury A, Olander A. Tewksbury A, et al. Ment Health Clin. 2016 Jun 29;6(4):185-190. doi: 10.9740/mhc.2016.07.185. eCollection 2016 Jul. Ment Health Clin. 2016. PMID: 29955468 Free PMC article.
-
Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review.
Junqueira DR, Bennett D, Huh SY, Casañas I Comabella C. Junqueira DR, et al. Pharmaceut Med. 2023 Mar;37(2):153-166. doi: 10.1007/s40290-023-00462-2. Epub 2023 Feb 17. Pharmaceut Med. 2023. PMID: 36800148 Free PMC article. Review.
-
Kelly DL, Wehring HJ, Earl AK, Sullivan KM, Dickerson FB, Feldman S, McMahon RP, Buchanan RW, Warfel D, Keller WR, Fischer BA, Shim JC. Kelly DL, et al. BMC Psychiatry. 2013 Aug 22;13:214. doi: 10.1186/1471-244X-13-214. BMC Psychiatry. 2013. PMID: 23968123 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources